MediWound Ltd. (MDWD) company profile
Close on Nov 16, 2026Market cap $173.92MP/E –Yield –
About MediWound
Medicinal Chemicals & Botanical Products, SIC 2833
MediWound Ltd. is a biopharmaceutical company that develops and commercializes therapeutics for burn care and wound management. Its primary products and pipeline product candidates include NexoBrid and EscharEx. The company serves healthcare providers and institutional partners, collaborating with government organizations such as the United States Biomedical Advanced Research and Development Authority, commercial pharmaceutical partners including Vericel and Teva, and regional burn centers and medical units.
The company is headquartered in Yavne, Israel, where it is also incorporated. Its operational scale and geographic presence span multiple countries, including the United States, Israel, and several European nations such as Germany, Italy, and Spain. MediWound operates dedicated manufacturing facilities to produce intermediate drug substances and finished goods for its research programs, clinical trials, and international commercial supply.
Summary of the business section of MediWound's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MediWound Ltd.
- Headquarters
- Yavne, L3
- Address
- 42 Hayarkon Street 8122745
- Phone
- 972779714100
- Website
- mediwound.com
- Employees
- 35, Dec 31, 2025
- Industry
- Medicinal Chemicals & Botanical Products
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Somekh Chaikin, Tel Aviv, Israel
Stock & identifiers
- Ticker
- MDWD
- Exchange
- Nasdaq
- IPO date
- Mar 21, 2014
- Shares outstanding
- 13M, Dec 31, 2025
- Filer category
- Accelerated filer
- Stock splits
- 1-for-7 reverse, Dec 20, 2022
- SEC CIK
- 1593984
- CUSIP
- M68830104
- FIGI
- BBG005ZPKRQ4
- Share class FIGI
- BBG005ZPKSG3
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ofer Gonen | Chief Executive Officer | 66,019 |
| Shmuel Hess | COO & Chief Commercial Officer | 0 |
| Ety Klinger | Chief Medical Officer | 1,500 |
| Yaron Meyer | EVP, GC & Corp. Secretary | 2,357 |
| Yaakov Aya Ben | VP Clinical & Reg. Affairs | 125 |
| Kalfon Hana Luxenburg | Chief Financial Officer | 3,000 |
| Nachum Shamir | Director | 72,151 |
| David Morton Fox | Director | 28,817 |
| Samuel Rubinstein | Director | 750 |
| Vickie Rae Driver | Director | 750 |
| Stephen T. Wills | Director | 750 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 21, 2014
- Offer price
- $14.00
- Securities offered
- 5,000,000
- Gross proceeds
- $70.00M
- Exchange
- Nasdaq
- First trading day
- Mar 20, 2014
- First-day close
- $17.27+23.4%
- Lock-up ends (est.)
- Sep 16, 2014
“Our ordinary shares have been approved for listing on the NASDAQ Global Market under the symbol "MDWD." Per Share Total Public offering price $ 14.00 $ 70,000,000 Underwriting discount(1) $ 0.98 $ 4,900,000 Proceeds, before expenses, to us $ 13.02 $ 65,100,000 (1) See "Underwriting" for a description of the compensation payable to the underwriters.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“Our research and development team is located at our facilities in Yavne and Gan-Rave, Israel, and consists of 35 employees as of December”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 21, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 12, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?